Carcinoma de mama: novos conceitos na classificação

Vieira, Dioracy Fonterrada; Düfloth, Rozany Mucha; Schmitt, Fernando; Zeferino, Luíz Carlos

doi:10.1590/s0100-72032008000100008

Cited by 9 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The triple-negative group has worse prognosis and requires specific treatments (37,38). It is expected that patients with this profile will not benefit from the use of trastuzumab or hormonal therapies, which results in challenges when prescribing and administering treatments in patients with triple-negative mammary tumor (39,40).…”

Section: Introductionmentioning

confidence: 99%

Prognostic phenotypic classification for canine mammary tumors

et al. 2019

View full text Add to dashboard Cite

Mammary neoplasms are a heterogeneous form of disease, and in order to determine its course and biological features with more accuracy, investigations based on tumor phenotypes are required. The aim of the present study was to propose and validate a phenotypic classification for canine mammary tumors and to assess any association between clinicopathological characteristics, survival and prognosis. For the immunohistochemistry analysis, the primary antibodies against estrogen receptor-α, progesterone receptor, human epidermal growth factor receptor 2 (HER-2)/neu and E-cadherin were used. A total of 110 canine mammary tumors were investigated; 42 tumors were classified as luminal A, 41 as luminal B, 17 as triple-negative and 10 as HER-2-positive. The luminal A and B phenotypes were associated with improved prognosis, whereas HER-2positive and triple-negative tumors were more aggressive, and exhibited a significant association with the occurrence of metastasis, a worse Tumor-Node-Metastasis classification and shorter survival time (P<0.05). In addition, there were different levels of E-cadherin expression intensity observed among the four tumor profiles investigated. Luminal A and B phenotypes presented an upregulation of E-cadherin compared with the HER-2 positive and triple-negative phenotypes (P<0.05). From the results of the present study, the proposed immunohistochemical panel and phenotypic classification techniques could be useful diagnostic tools with a good technical applicability in veterinary oncology. The analysis of E-cadherin expression in the panel of tumor markers allowed a more accurate classification for determining the biological features of the mammary tumor.

show abstract

Section: Introductionmentioning

confidence: 99%

Prognostic phenotypic classification for canine mammary tumors

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Due to its wide clinical, biological, and morphological heterogeneity, breast cancer is a complex disease. Tumors with similar clinical and histological profiles can have different prognoses and therapeutic responses (Cirqueira, Moreira, Soares, & Freitas‐Júnior, 2011; Vieira, Dufloth, Schmitt, & Zeferino, 2008). This diversity is mainly due to the combined expression of hormone receptors for progesterone (PR) and estrogen (ER), and the receptor of the epidermal growth factor 2 (HER2), that confer at least four main molecular subtypes of breast cancer (Luminal A or B for ER/PR positives, HER2 amplified and triple negative tumors).…”

Section: Introductionmentioning

confidence: 99%

Chimarrão consumption and prognostic factors in breast cancer: Correlation with antioxidants and blood caffeine levels

Calixto

Rech

Santos

et al. 2020

Phytotherapy Research

View full text Add to dashboard Cite

Breast cancer is the second most common malignancy among women. Ilex paraguariensis A. St. Hil, known as yerba mate, is widely consumed in southern Brazil as a hot infusion drink known as chimarrão. This herb has a complex chemical composition and is rich in antioxidants, which may interfere in the course of chronic inflammatory diseases as breast cancer. This study investigated the impact of chimarrão consumption on the clinicopathological profile of women with breast cancer attended at Francisco Beltrão Cancer Hospital, Paraná, Brazil. Blood antioxidants and caffeine profiles were assessed. Decreases in reduced glutathione and metallothionein levels, and increase in catalase activity were observed among breast cancer patients that were chimarrão consumers. The levels of circulating caffeine in breast cancer patients with luminal A tumors were higher than those in patients with luminal B and HER‐2 subtypes. Furthermore, overweight patients presented higher caffeine levels than the eutrophic ones. It was found positive associations between chimarrão intake and high body mass index, and chimarrão intake and menopause at diagnosis. Altogether, these findings suggest that chimarrão consumption affects the blood antioxidants of breast cancer patients, and that the caffeine present in this mixture may favor the development of tumor of good prognosis. Highlights Chimarrão consumption may affect the course of chronic inflammatory diseases, as breast cancer. Chimarrão intake changed blood antioxidants in breast cancer patients who were current consumers when compared to the non‐consumers ones. High levels of caffeine were detected in patients bearing luminal A tumors, suggesting a protective role.

show abstract

“…Staging of tumors according to TNM classification allows the tumor characterization, but it failures to therapeutic indication (Vieira et al, 2008). Perou et al (2000) characterized the variation of gene expression patterns in breast tumor samples using DNA microarray.…”

Section: Introductionmentioning

confidence: 99%

Crosstalk between Oxidative Stress Signaling and HER2 Pathway in Breast Cancer

Victorino¹,

Aranome²,

Campos³

et al. 2014

American Journal of Immunology

View full text Add to dashboard Cite

About 20% of breast cancer patients overexpress the Human Epidermal growth factor Receptor-2 (HER2), also known as ErbB2. HER2overexpression is associated with enhanced tumor malignancy and its overexpression is related to specific target therapy against breast tumors and other cancers. HER2-mediated pathways in tumor cells act on behalf of the tumor conferring aggressive characteristics. Several reports demonstrated the occurrence of toxicity during the anti-HER2 therapy and this fact has been associated with the generation of reactive species and oxidative stress. However, the link between HER2 and oxidative stress signaling is still poorly understood. The aim of this review is to point out the interplay between oxidative stress and HER2 signaling in breast cancer. An overview regarding HER2 biology and oxidative stress pathways is provided with a special focus in studies that implicate on HER2-generation of reactive species and oxidative stress during trastuzumab-based treatments.

show abstract

Carcinoma de mama: novos conceitos na classificação

Cited by 9 publications

References 0 publications

Prognostic phenotypic classification for canine mammary tumors

Prognostic phenotypic classification for canine mammary tumors

Chimarrão consumption and prognostic factors in breast cancer: Correlation with antioxidants and blood caffeine levels

Crosstalk between Oxidative Stress Signaling and HER2 Pathway in Breast Cancer

Contact Info

Product

Resources

About